Human Pancreas Analysis Program (HPAP) (U01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to continue the mission of the existing Human Pancreas Analysis Program (HPAP). This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues from patients with type 1 diabetes (T1D), beta cell specific autoimmunity, or rare forms of islet dysfunction that may inform understanding of the pathogenesis of T1D , as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues and expand the existing PANC DB open-access resource database.  HPAP is a component of HIRN, created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional human beta cell mass.

 A Companion Funding Opportunity (RFA-DK-18-016) will support the expansion of the operational scope of the existing HPAP to the study of pancreata recovered from tissue donors with Type 2 Diabetes (T2D) and related metabolic disorders.


  • Letter of Intent Due Date(s): January 26, 2019
  • Application Due Date(s): February 26, 2019

​RFA-DK-18-015 Expiration Date February 27, 2019

Agency Website



Amount Description

Application budgets are limited to $3 million direct costs per year.
The maximum project period is 4 years

Funding Type





Medical - Basic Science
Medical - Translational

External Deadline

February 26, 2019